Finn
VCYT Diagnostics · Oncology · Genomic testing · Thesis updated November 8, 2026

Core tests face new rivals as margin pressure grows

01 Running thesis

A defensive transition

Veracyte is moving from a period of unhindered growth into a more defensive stance. While third quarter 2026 testing revenue grew a solid 15 percent to $146.4 million, the flagship Decipher Prostate test missed volume expectations. The core issue is competitive distraction. Novel digital pathology and artificial intelligence tools are capturing physician attention, forcing sales teams to spend more time explaining differences rather than closing new orders.

To defend its market share and stabilize adoption, Veracyte is increasing its urology sales force by 30 percent. This heavy investment will pressure near-term margins and pull expected early 2027 profitability below previous targets. The key question for investors is whether a larger team can successfully reaccelerate Decipher growth without diluting focus on newer products.

The bull case still rests on a highly profitable testing engine and a newly completed bladder cancer portfolio. Afirma thyroid testing continues to deliver exceptional growth, and the recent acquisition of Convergent Genomics adds the UroAmp platform. This gives Veracyte a comprehensive bladder cancer offering spanning tissue, blood, and urine tests.

Execution risk has increased. The company must prove it can absorb the costs of a larger sales team, fend off digital pathology alternatives, and simultaneously launch its major pipeline products like TrueMRD.

Nov 2026▼Third quarter 2026 results revealed slowing Decipher Prostate growth and margin pressure from a planned 30 percent sales force expansion.
Jul 2026▲Second quarter 2026 results showed continued strength with testing revenue up 19 percent year-over-year. The company officially launched its TrueMRD and Prosigna LDT products.
May 2026→The first quarter 2026 filing confirmed strong earnings and did not add new material risk factors. Testing revenue rose 26 percent in the quarter.
May 2026▲First quarter 2026 was a clear beat and raise. Decipher volume grew 24 percent, Afirma volume grew 12 percent, and management raised full-year guidance.
Feb 2026→The 2025 annual report confirmed the prior view, keeping the focus on Decipher, Afirma, and planned 2026 product launches.
Feb 2026▲Fourth quarter 2025 showed strong execution and profitability ahead of schedule. Management gave clearer timing for new test launches.
Nov 2025→The third quarter 2025 filing confirmed continued testing strength and no new material risk factors.
02 Business model

Evidence turns into paid tests

Veracyte makes money when doctors order its cancer tests and payers, such as Medicare or private insurers, agree to pay for them. Most revenue comes from U.S. laboratory developed tests, which are diagnostic tests designed and run inside a certified lab.

The business works best when clinical data proves that a test changes patient care. Solid evidence and guideline inclusion help doctors trust the test, raising overall volume. Better payer contracts and clear billing then raise the cash collected per test.

This model requires constant education and defense. When new technologies like digital pathology enter the market, sales teams must spend time contextualizing molecular testing instead of core selling. This slows down the pace of new adoption.

Because testing is nearly all of total revenue, reimbursement is the central pillar. The company relies on its specialized sales channels to defend existing tests and launch new ones simultaneously.

03 Product portfolio

Core tests fund new bets

Growth engine

Decipher Prostate

The historical main growth driver, currently facing adoption headwinds from digital pathology alternatives.

Cash cow

Afirma

A thyroid nodule test that continues to be a steady pillar for the company with durable volume growth.

Option

TrueMRD

Launched for muscle-invasive bladder cancer, TrueMRD looks for small signs that cancer may be returning.

Option

UroAmp

A proprietary urinary tumor DNA platform added via the 2026 Convergent Genomics acquisition to expand bladder cancer testing.

Option

Prosigna LDT

A breast cancer test that represents a major growth option, depending on clinical evidence and share gains.

Steady

Decipher Bladder

An earlier bladder cancer test that helps Veracyte build deeper ties with urologists.

04 Business segments

Almost entirely a testing business

Testing96%growing fast
Product3%growing fast
Biopharmaceutical and other0%declining

The mix uses third quarter 2026 revenue. Testing makes up nearly 97 percent of total sales, placing heavy reliance on the Decipher and Afirma franchises.

05 Risk factors

What could break the story

Digital pathology distraction

High impact · High odds

New digital pathology and artificial intelligence tools are drawing physician attention away from core molecular tests. The sales team must spend more time contextualizing these tools, which slows core product adoption.

We watchListen for updates on sales cycle length and Decipher volume growth.

Margin pressure from sales expansion

Medium impact · High odds

Veracyte is expanding its urology sales force by 30 percent to defend market share. This heavy investment will pull near-term profitability below previous targets.

We watchTrack operating margins and first quarter 2027 EBITDA performance.

Reimbursement pressure

High impact · Medium odds

Veracyte recognizes testing revenue based on what it expects to collect. A negative coverage change from Medicare or lower payment rates could hurt revenue and margin immediately.

We watchTrack Medicare rate updates, commercial payer contracts, and any rise in claims denials.

LDT regulation adds cost and delay

Medium impact · Medium odds

The FDA rule issued in 2024 phases out broad enforcement discretion for many laboratory developed tests. Newer tests could face more stringent review, raising costs and stretching future launch timelines.

We watchWatch FDA implementation dates and spending tied to regulatory work.
06 Quick answers

In one breath

What does Veracyte actually sell?

Veracyte sells genomic cancer tests. These tests read patterns in tumor or tissue samples to help doctors decide whether a patient needs more treatment or can avoid it.

Why is Decipher important to Veracyte?

Decipher Prostate is the company's main growth engine. However, its recent growth has slowed as doctors explore new digital pathology alternatives.

Why does reimbursement matter so much?

Most Veracyte revenue comes from tests that need payment from Medicare or insurers. If payers cut rates or deny more claims, profit falls even when doctors order tests.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Veracyte Q3 2026 Form 10-Q
  2. Veracyte Q2 2026 Form 10-Q
  3. Veracyte Q1 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Veracyte, Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today